drugset / Trial / NCT01446042

Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism

NCT01446042

Phase 3 Completed 306 enrolled Acerus Pharmaceuticals Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy (based on the pharmacokinetic profile of testosterone) and safety of TBS-1 in the treatment of hypogonadal men

Timeline

Start
2011-09
Primary completion
2012-12
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 11 mg Intranasal

Indications